SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently the subject of intense community debate, with investors closely watching its struggle to maintain a key psychological resistance level near $1,800. While proponents highlight growing institutional adoption and potential upcoming regulatory clarity as catalysts for a long-term breakout, skeptics remain wary of ongoing price volatility and the asset's historical tendency to face rejection at current levels.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

The Grayscale Ethereum Mini Trust is trending as investors weigh significant institutional inflows against ongoing volatility driven by broader crypto market liquidations and geopolitical tensions. Market sentiment is heavily divided, with active community discussions focusing on Ethereum's long-term utility versus its recent underperformance relative to other assets.

Shake Shack, Inc. engages in the operation and licensing of Shake Shack restaurants which serve burgers, hot dogs, crinkle cut fries, shakes, frozen custard, beer, wine, and related products. The company was founded by Daniel Harris Meyer on September 23, 2014 and is headquartered in New York, NY.

Shake Shack Inc - Ordinary Shares - Class A

Shake Shack is seeing significant volatility as investors debate its valuation relative to fast-casual peers, while recent insider purchases from the founder and CEO are fueling community speculation about a potential bottom. Sentiment remains polarized between those focused on the brand's long-term expansion and those concerned about margin pressures, high menu pricing, and macroeconomic headwinds.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is currently facing a sharp selloff that has pushed the stock to multi-year lows, driven by mounting consumer frustration over shrinking portion sizes, aggressive pricing, and concerns that the fast-casual chain is losing its competitive edge. While some traders view these depressed levels as a rare valuation opportunity for a long-term turnaround, the community is actively debating whether current management is failing to address deep-seated brand and service issues that are eroding customer loyalty.

OpenAI

OpenAI is dominating community sentiment as the company balances a high-stakes legal dispute over its nonprofit mission and a potential massive IPO valuation against scrutiny over its aggressive compute spending and model development. Investors are closely monitoring its evolving partnerships, particularly its shift away from exclusive cloud arrangements and expansion into new revenue streams like advertising.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is facing volatility as investors weigh the stock's strong cash flow and multi-billion dollar contract backlog against the uncertainties surrounding its pending Valaris merger and antitrust regulatory reviews. The community is actively discussing the potential for operational gaps in the 2026 schedule and debating whether current market skepticism creates a buying opportunity for a cash-generative asset in a tightening energy market.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph (HBAR) is currently facing significant volatility and community frustration as investors debate the impact of the token's circulating supply and long-term utility against its enterprise adoption story. While some retail holders are aggressively averaging down and staking their tokens, others are expressing heavy skepticism, citing concerns over corporate governance and stagnant price action compared to broader market trends.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as investors debate its long-term viability amid ongoing price volatility, with the community split between those accumulating at lower levels based on technical developments and those viewing it as a declining asset. Discussions are heavily focused on its evolving tokenomics, the transition to Polkadot 2.0, and whether its enterprise-grade infrastructure can eventually drive institutional adoption.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is driving significant investor interest as the market anticipates the upcoming July PDUFA date for its lead breast cancer drug, gedatolisib. The community is actively debating the potential for FDA approval, the impact of recent institutional financing, and the high-conviction sentiment among analysts who continue to issue positive ratings.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently capturing significant attention as investors react to positive clinical data and bullish analyst coverage, with a notable uptick in institutional ownership and high short interest fueling speculation of a potential squeeze. Community discourse remains divided between long-term holders highlighting the company's novel ITK inhibitor platform and skeptics closely monitoring the stock's volatility and reliance on speculative pipeline readouts.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional antiCTLA-4 antibody, plus balstilimab (BAL), an antiPD-1 antibody, in patients...

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab (BOT), an Fc-enhanced multifunctional antiCTLA-4 antibody, plus balstilimab (BAL), an antiPD-1 antibody, in patients with microsatellite...

Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGEN Early Access Revenues Signal a New Path Ahead of Approval

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.

Is Agenus Stock a Hold Amid Valuation and Funding Risks?

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.

AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Agenus Inc. (Agenus) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:45 a.m. ET. To participate in...

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

ImmunityBio: Anktiva Explained and What Comes Next

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

This account has been verified as an official AGEN representative.

Verified Account

Agenus Communications

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.35
Prev Close	$3.24
Open	$3.24
Dividend Yield	0.00%
50-Day Moving Average	$3.35
Beta	1.93
Avg. Volume	840,810.11
PE Ratio	2.01

52-Week High	$7.04
52-Week Low	$2.71
Market Capitalization	$139.5M
EPS (Annual)	-$0.0034
Price to Book	-0.58
Revenue Per Employee	$1.41M

Feed

News

Sentiment

Earnings

Fundamentals

Info

AGENAgenus Inc

Latest AGEN News